Other languages Apollomics, Inc.

Equities

APLM

KYG0411D1079

Delayed Nasdaq Other stock markets 10:49:01 27/06/2024 pm IST			5-day change	1st Jan Change
0.2055 ^USD	+3.74%		+5.17%	-78.72%

04/06	Apollomics Announces Vebreltinib Data At the 2024 American Society of Clinical Oncology Annual Meeting	CI
08/05	Apollomics, Inc. Appoints Robert Lin to the Board of Directors	CI

Other languages

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Apollomics Announces Vebreltinib Data At the 2024 American Society of Clinical Oncology Annual Meeting	04/06
Apollomics, Inc. Appoints Robert Lin to the Board of Directors	09/05
Avistone Biotechnology Co. Ltd. Receives Approval from the National Medical Products Administration of China for Vebrelinib (APL-101) for the Treatment of Gliomas with Met Fusion Gene	25/04
Predicine, Inc. Announces Collaboration with Apollomics, Inc. to Develop Predicinecare as A Companion Diagnostic Assay in Lung Cancer	06/04
Apollomics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/03
Apollomics Gets Nasdaq Noncompliance Notice	20/01
Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia	03/01
Top Premarket Gainers	27/11
Apollomics Announces Two New Cohorts in Global Phase 2 Sparta Study of Vebreltinib in Non-Small Cell Lung Cancer and Other Solid Tumors with Met Dysregulation	31/23/31
Sector Update: Health Care Stocks Slip in Late Afternoon	28/23/28
Sector Update: Health Care	28/23/28
Apollomics Shares Soar on Experimental Drug's Efficacy in Brain Tumor Patient	28/23/28
Wall Street Set to Open Higher Friday; Core Inflation Rises 0.3% Matching Forecast	27/23/27
US Futures Mixed as Investors Look Toward Personal Income, Consumer Sentiment Reports	27/23/27
Top Premarket Gainers	27/23/27
Apollomics Inc. Announces Report of Activity of Vebrelinib in Glioblastoma Multiforme with PTPRZ-MET Fusion	26/23/26
Apollomics Inc. Announces Efficacy of Vebrelinib in NSCLC Patients with MetEx14 Skipping Mutation Achieving an Overall Response Rate of 75%	23/23/23
Apollomics, Inc. Announces Presentations of Vebreltinib Data at ESMO 2023	17/23/17
Apollomics, Inc. Reports Earnings Results for the Half Year Ended June 30, 2023	29/23/29
Apollomics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	29/23/29

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Apollomics, Inc.

Equities

APLM

KYG0411D1079

Other languages

Filters